When genomics outpaces insurance: the fight to treat rare cancers

Genomic science is rapidly revealing what drives individual cancers — but insurance coverage isn't keeping up. Mason Henderson, a 21-year-old Texan diagnosed with diffuse hemispheric glioma (H3-G34 mutant), a brain tumor so rare the WHO only named it in 2021, faced repeated denials for olaparib (Lynparza) — a drug his neuro-oncologists believed was biologically justified based on his tumor's genetic profile. His pharmacy benefit manager and his county's self-insured health plan both refused coverage, citing the absence of an FDA-approved indication for his diagnosis. After a six-week battle — including a viral social media campaign — AstraZeneca's patient assistance program finally shipped the drug. Henderson died on May 4, having taken it for nearly two months.

His case is far from unique. About a quarter of all U.S. cancer diagnoses are classified as rare, and many lack targeted, FDA-approved therapies — even when molecular testing points to a viable treatment option.

Key Takeaways:

• Insurers typically require FDA-label alignment or established guidelines before approving coverage — criteria that rarely exist for rare cancers
• Nine FDA-approved "tissue agnostic" drugs can be used based on tumor mutation regardless of organ origin, but they remain a small minority
• Programs like ASCO's TAPUR trial offer off-label treatments at no cost to late-stage patients, with ~50% of participants showing benefit — but primary brain tumors are often excluded
• Experts argue that genomic-based cancer classification, rather than organ-of-origin, could reshape treatment and coverage frameworks

Why it matters: As next-generation tumor sequencing becomes standard practice, the mismatch between what science can identify and what insurers will pay for is leaving rare cancer patients with few options — and families fighting bureaucracy instead of disease.